Liquidia Shares Jump After US Supreme Court Rejects United Therapeutics' Appeal in Patent Dispute

MT Newswires Live

Oct 08, 2024

Liquidia (LQDA) shares climbed more than 14% in recent Monday trading after the US Supreme Court denied a request by United Therapeutics (UTHR) for a review of previous rulings over a patent infringement dispute between the two companies.

The high court's rejection of United Therapeutic's petition means that the US Court of Appeals for the Federal Circuit's 2023 ruling affirming the decision of Patent Trial and Appeal Board in 2022 against United Therapeutics' patent claims is "final and not subject to further appeal," Liquidia said

The board had ruled against United Therapeutics' patent covering claims related to Liquidia's Yutrepia, or treprostinil, inhalation powder to treat adults with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

Liquidia said the US Food and Drug Administration's final approval for Yutrepia may occur after the three-year regulatory exclusivity for United Therapeutics' Tyvaso DPI for the treatment of similar ailment expires on May 23 next year.

United Therapeutics did not immediately reply to MT Newswires' request for comment. Its shares were down about 1%.

Price: 11.51, Change: +1.48, Percent Change: +14.71

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2473485309"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2473485309\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2473485309?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-08 00:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2473485309","market":"fut","top_or_hot":-1,"title":"Liquidia Shares Jump After US Supreme Court Rejects United Therapeutics' Appeal in Patent Dispute","media":"MT Newswires Live","content":"<html><body><p> Liquidia (LQDA) shares climbed more than 14% in recent Monday trading after the US Supreme Court denied a request by United <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (UTHR) for a review of previous rulings over a patent infringement dispute between the two companies.</p><p>The high court's rejection of United Therapeutic's petition means that the US Court of Appeals for the Federal Circuit's 2023 ruling affirming the decision of Patent Trial and Appeal Board in 2022 against United Therapeutics' patent claims is \"final and not subject to further appeal,\" Liquidia said</p><p>The board had ruled against United Therapeutics' patent covering claims related to Liquidia's Yutrepia, or treprostinil, inhalation powder to treat adults with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.</p><p>Liquidia said the US Food and Drug Administration's final approval for Yutrepia may occur after the three-year regulatory exclusivity for United Therapeutics' Tyvaso DPI for the treatment of similar ailment expires on May 23 next year.</p><p>United Therapeutics did not immediately reply to MT Newswires' request for comment. Its shares were down about 1%.</p><p>Price: 11.51, Change: +1.48, Percent Change: +14.71</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Liquidia Shares Jump After US Supreme Court Rejects United Therapeutics' Appeal in Patent Dispute</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLiquidia Shares Jump After US Supreme Court Rejects United Therapeutics' Appeal in Patent Dispute\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-10-08 00:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Liquidia (LQDA) shares climbed more than 14% in recent Monday trading after the US Supreme Court denied a request by United <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (UTHR) for a review of previous rulings over a patent infringement dispute between the two companies.</p><p>The high court's rejection of United Therapeutic's petition means that the US Court of Appeals for the Federal Circuit's 2023 ruling affirming the decision of Patent Trial and Appeal Board in 2022 against United Therapeutics' patent claims is \"final and not subject to further appeal,\" Liquidia said</p><p>The board had ruled against United Therapeutics' patent covering claims related to Liquidia's Yutrepia, or treprostinil, inhalation powder to treat adults with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.</p><p>Liquidia said the US Food and Drug Administration's final approval for Yutrepia may occur after the three-year regulatory exclusivity for United Therapeutics' Tyvaso DPI for the treatment of similar ailment expires on May 23 next year.</p><p>United Therapeutics did not immediately reply to MT Newswires' request for comment. Its shares were down about 1%.</p><p>Price: 11.51, Change: +1.48, Percent Change: +14.71</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LQDA","symbol_name":"Liquidia Technologies Inc","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2473485309","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2473485309","pubTimestamp":1728319236,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Liquidia  shares climbed more than 14% in recent Monday trading after the US Supreme Court denied a request by United Therapeutics  for a review of previous rulings over a patent infringement dispute between the two companies.The high court's rejection of United Therapeutic's petition means that the US Court of Appeals for the Federal Circuit's 2023 ruling affirming the decision of Patent Trial and Appeal Board in 2022 against United Therapeutics' patent claims is \"final and not subject to further appeal,\" Liquidia saidThe board had ruled against United Therapeutics' patent covering claims related to Liquidia's Yutrepia, or treprostinil, inhalation powder to treat adults with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.Liquidia said the US Food and Drug Administration's final approval for Yutrepia may occur after the three-year regulatory exclusivity for United Therapeutics' Tyvaso DPI for the treatment of similar ailment expires","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LQDA":"Liquidia Technologies Inc","BK4139":"生物科技","BK4532":"文艺复兴科技持仓","BK4007":"制药","UTHR":"美国联合医疗","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC"},"translate_title":"美国最高法院驳回United Therapeutics专利纠纷上诉后，Liquidia股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LQDA":0.9,"UTHR":1},"content_text":"Liquidia (LQDA) shares climbed more than 14% in recent Monday trading after the US Supreme Court denied a request by United Therapeutics (UTHR) for a review of previous rulings over a patent infringement dispute between the two companies.The high court's rejection of United Therapeutic's petition means that the US Court of Appeals for the Federal Circuit's 2023 ruling affirming the decision of Patent Trial and Appeal Board in 2022 against United Therapeutics' patent claims is \"final and not subject to further appeal,\" Liquidia saidThe board had ruled against United Therapeutics' patent covering claims related to Liquidia's Yutrepia, or treprostinil, inhalation powder to treat adults with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.Liquidia said the US Food and Drug Administration's final approval for Yutrepia may occur after the three-year regulatory exclusivity for United Therapeutics' Tyvaso DPI for the treatment of similar ailment expires on May 23 next year.United Therapeutics did not immediately reply to MT Newswires' request for comment. Its shares were down about 1%.Price: 11.51, Change: +1.48, Percent Change: +14.71","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}